RxDoctor Payments Data

Lindsay Foust, DPM

Podiatrist · Paris, TNNPI 1609152230

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (54.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Arthrex at 43.1% of the total. Reporting peaked in 2019 at $3,828 and has fallen 75.3% since, to $946 in 2025.

$8,769in general payments, 2019–2025

Across 83 payments — averaging $105.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Arthrex$4K
  • Gentleman Orthopedic Solutions$3K
  • Treace Medical Concepts, Inc.$1K
  • Averitas Pharma Inc.$111
  • Amgen$109
  • Smith+Nephew$63
  • plus $326 from 12 others

What the payments were for

  • Travel & lodging$1,73020%
  • Food & beverage$2,26626%
  • Education$4,77254%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,769 in reported general payments places this provider in the 85th percentile of 105 podiatrist providers in Tennessee.

See all podiatrist providers in Tennessee

Medicare billing

Part B allowed, 2024
$134,610
Medicare patients
461
Services billed
1,863

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.13$9,361
Ammonium Lactate59$919
Diclofenac Sodium75$802
Methylprednisolone69$458
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen33$419
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen40$381
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav22$269
Mupirocin42$263
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip16$253
Cephalexin20$152
Doxycycline Hyclate17$152
Ibuprofen14$147
Meloxicam68$124
Ketoconazole13$97
Triamcinolone Acetonide19$93

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$63$9,36113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 105 podiatrist providers in Tennessee.

Other podiatrist in Paris

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →